Hiroshi Tsubamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hiroshi Tsubamoto has a total of 164 co-authors. Here are the top co-authors by number of shared publications:
Hiroaki Shibahara
Department of Obstetrics and Gynecology, School of Medicine Hyogo Medical University Nishinomiya Hyogo Japan
23 shared publicationsTomoko Ueda
Obstetrics and Gynecology, Hyogo Medical University School of Medicine, Nishinomiya, JPN
15 shared publicationsKayo Inoue
Department of Obstetrics and Gynecology, Hyogo Medical Univesity, Nishinomiya, Hyogo, Japan
14 shared publicationsKazuko Sakata
Department of Obstetrics and Gynecology, School of Medicine, Hyogo Medical University, Nishinomiya, Japan
12 shared publicationsSeiichi Hirota
Department of Surgical Pathology, School of Medicine, Hyogo Medical University, Hyogo, Japan
8 shared publicationsYumi Takimoto
Department of Obstetrics and Gynecology, School of Medicine, Hyogo Medical University, Nishinomiya, Japan
8 shared publications
Latest Publications
- Open Access
- 15 May 2026
- Published by Springer Nature in Cureus
- Vol. 18 (5) , e108929
Pseudoaneurysm of the Internal Pudendal Artery Causing Delayed Vaginal Hemorrhage After Robotic-Assisted Total Hysterectomy: A Case Report
Pseudoaneurysm is a rare but potentially life-threatening cause of delayed postoperative hemorrhage. Although pseudoaneurysms are well described after obstetric and gynecologic procedures, involvement of the internal pudendal artery after hysterectomy is extremely rare. A 50-year-old nulligravid woman underwent robot-assisted total hysterectomy with bilateral salpingectomy for symptomatic uterine leiomyomas. During transvaginal specimen retrieval, vaginal wall lacerations occurred bilaterally and were sutured intraoperatively. The postoperative course was uneventful, and the patient was discharged on postoperative day 5. On postoperative day 22, she presented with vaginal bleeding originating from the sutured site on the right vaginal wall. Initial transvaginal suturing achieved temporary hemostasis; however, recurrent bleeding occurred later the same day. Three-dimensional computed tomography angiography revealed active extravasation from a pseudoaneurysm arising from a branch of the right internal pudendal artery. Transcatheter arterial embolization using gelatin sponge particles successfully controlled the bleeding. Transvaginal specimen retrieval caused pseudoaneurysm formation of the internal pudendal artery. Transcatheter arterial embolization is an effective and minimally invasive treatment option.
- 15 May 2026
- Published by Springer Nature in Cureus
- Vol. 18 (5) , e108929
Open AccessPseudoaneurysm of the Internal Pudendal Artery Causing Delayed Vaginal Hemorrhage After Robotic-Assisted Total Hysterectomy: A Case Report
Pseudoaneurysm is a rare but potentially life-threatening cause of delayed postoperative hemorrhage. Although pseudoaneurysms are well described after obstetric and gynecologic procedures, involvement of the internal pudendal artery after hysterectomy is extremely rare. A 50-year-old nulligravid woman underwent robot-assisted total hysterectomy with bilateral salpingectomy for symptomatic uterine leiomyomas. During transvaginal specimen retrieval, vaginal wall lacerations occurred bilaterally and were sutured intraoperatively. The postoperative course was uneventful, and the patient was discharged on postoperative day 5. On postoperative day 22, she presented with vaginal bleeding originating from the sutured site on the right vaginal wall. Initial transvaginal suturing achieved temporary hemostasis; however, recurrent bleeding occurred later the same day. Three-dimensional computed tomography angiography revealed active extravasation from a pseudoaneurysm arising from a branch of the right internal pudendal artery. Transcatheter arterial embolization using gelatin sponge particles successfully controlled the bleeding. Transvaginal specimen retrieval caused pseudoaneurysm formation of the internal pudendal artery. Transcatheter arterial embolization is an effective and minimally invasive treatment option.
- Open Access
- 29 November 2025
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 45 (12) , 5255-5266
Inhibition of Cholesterol Transport from Lysosomes by Itraconazole Repolarizes Tumor-associated Macrophages to Anti-tumor M1 type
Background/Aim: Targeting tumor-associated macrophages (TAMs) represents a promising strategy for next-generation immunotherapy. This study investigates the underlying mechanisms of TAM repolarization from the pro-tumorigenic M2 phenotype to the anti-tumorigenic M1 phenotype induced by itraconazole (ITZ). Materials and Methods: M2 macrophages derived from THP-1 cells were used in all experiments, and ITZ was administered at a concentration of 10−5 M. Morphological changes were monitored via time-lapse imaging. Single-cell RNA sequencing (scRNA-seq) and triple-color immunostaining for organelles, cholesterol, and the M1 marker interleukin (IL)-1β were performed with and without ITZ treatment. For inhibition studies, β-cyclodextrin polyrotaxane (βCD-PRX), a compound that removes cholesterol from lysosomes, was used. The effects were assessed by time-lapse imaging and western blot analysis of the M2 marker CD163. Results: Following ITZ treatment, a subpopulation of M2 macrophages exhibited morphological changes, shedding dendrites and migrating, indicative of an M1-like phenotype. Additionally, intracellular lipid droplets enlarged and swelled. scRNA-seq analysis revealed that M2 macrophages with reduced lysosomal vesicle biogenesis transitioned to an M1-like phenotype and identified 1,142 significantly enriched pathways, including M1-related signaling activation and cholesterol metabolism and transport pathways. Immunofluorescence analysis confirmed that macrophages shifting toward an M1-like phenotype expressed IL-1β, with enlarged intracellular lipid droplets identified as cholesterol-containing lysosomes. Notably, M2 macrophages that had adopted an M1-like morphology in response to ITZ reverted to their original M2-like shape and exhibited increased CD163 expression following βCD-PRX treatment. Conclusion: Inhibition of lysosomal cholesterol release by ITZ reprogrammed M2 macrophages into an M1-like phenotype, revealing a novel mechanism that may serve as a foundation for developing innovative TAM-targeted immunotherapies.
- 29 November 2025
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 45 (12) , 5255-5266
Open AccessInhibition of Cholesterol Transport from Lysosomes by Itraconazole Repolarizes Tumor-associated Macrophages to Anti-tumor M1 type
Background/Aim: Targeting tumor-associated macrophages (TAMs) represents a promising strategy for next-generation immunotherapy. This study investigates the underlying mechanisms of TAM repolarization from the pro-tumorigenic M2 phenotype to the anti-tumorigenic M1 phenotype induced by itraconazole (ITZ). Materials and Methods: M2 macrophages derived from THP-1 cells were used in all experiments, and ITZ was administered at a concentration of 10−5 M. Morphological changes were monitored via time-lapse imaging. Single-cell RNA sequencing (scRNA-seq) and triple-color immunostaining for organelles, cholesterol, and the M1 marker interleukin (IL)-1β were performed with and without ITZ treatment. For inhibition studies, β-cyclodextrin polyrotaxane (βCD-PRX), a compound that removes cholesterol from lysosomes, was used. The effects were assessed by time-lapse imaging and western blot analysis of the M2 marker CD163. Results: Following ITZ treatment, a subpopulation of M2 macrophages exhibited morphological changes, shedding dendrites and migrating, indicative of an M1-like phenotype. Additionally, intracellular lipid droplets enlarged and swelled. scRNA-seq analysis revealed that M2 macrophages with reduced lysosomal vesicle biogenesis transitioned to an M1-like phenotype and identified 1,142 significantly enriched pathways, including M1-related signaling activation and cholesterol metabolism and transport pathways. Immunofluorescence analysis confirmed that macrophages shifting toward an M1-like phenotype expressed IL-1β, with enlarged intracellular lipid droplets identified as cholesterol-containing lysosomes. Notably, M2 macrophages that had adopted an M1-like morphology in response to ITZ reverted to their original M2-like shape and exhibited increased CD163 expression following βCD-PRX treatment. Conclusion: Inhibition of lysosomal cholesterol release by ITZ reprogrammed M2 macrophages into an M1-like phenotype, revealing a novel mechanism that may serve as a foundation for developing innovative TAM-targeted immunotherapies.
- 29 October 2025
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 51 (11) , e70117
Rare Intronic Variants Altering Splicing Cause Lynch Syndrome: Two Case Reports
Lynch syndrome (LS) is an autosomal‐dominant hereditary cancer syndrome caused by defective mismatch repair (MMR) genes. This report presents two cases of LS with rare intronic variants in MLH1 and MSH2 that affect splicing, leading to diagnostic challenges and implications for management. The first case involves a 50‐year‐old woman with a history of colorectal and endometrial cancers, identified with a MSH2 c.2458+976A>G variant, resulting in pseudo‐exon inclusion. The second case describes a 70‐year‐old woman with synchronous endometrial and cecal cancers, carrying an MLH1 c.545+4_545+5del variant, which caused exon 6 skipping. Both cases have strong familial and/or medical histories of LS‐related cancers, but no pathogenic variant has been detected by conventional genetic testing. In these cases, RNA sequencing played a crucial role in establishing a definitive diagnosis. These findings highlight the need for genetic testing beyond conventional exon‐focused sequencing to ensure accurate diagnosis and management.
- 29 October 2025
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 51 (11) , e70117
Rare Intronic Variants Altering Splicing Cause Lynch Syndrome: Two Case Reports
Lynch syndrome (LS) is an autosomal‐dominant hereditary cancer syndrome caused by defective mismatch repair (MMR) genes. This report presents two cases of LS with rare intronic variants in MLH1 and MSH2 that affect splicing, leading to diagnostic challenges and implications for management. The first case involves a 50‐year‐old woman with a history of colorectal and endometrial cancers, identified with a MSH2 c.2458+976A>G variant, resulting in pseudo‐exon inclusion. The second case describes a 70‐year‐old woman with synchronous endometrial and cecal cancers, carrying an MLH1 c.545+4_545+5del variant, which caused exon 6 skipping. Both cases have strong familial and/or medical histories of LS‐related cancers, but no pathogenic variant has been detected by conventional genetic testing. In these cases, RNA sequencing played a crucial role in establishing a definitive diagnosis. These findings highlight the need for genetic testing beyond conventional exon‐focused sequencing to ensure accurate diagnosis and management.
- 13 August 2023
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 49 (11) , 2761-2765
Fertility‐sparing management of stage IIIC serous borderline ovarian tumor: A case report of a 20‐year follow‐up
Multimodal treatment, including assisted reproductive technology, is necessary in young patients with advanced borderline ovarian tumors. However, the details of long-term follow-up cases have not been reported. In this report, a 19-year-old patient presented with a stage IIIC serous borderline tumor. The patient underwent five fertility-sparing surgeries. The tumor did not respond to any of the three lines of chemotherapy administered. Serological and radiological responses were observed following hormonal treatment with leuprorelin, followed by a fourth surgery. Before the planned fifth surgery for complete resection of both adnexa, cryopreservation of the fertilized eggs was performed. At age 36, when the disease-free interval exceeded the previous one, we proposed embryo transfer; however, she declined fertility treatment. The patient had developed rheumatoid arthritis and childbirth not a priority. The patient had lived without any evidence of disease for 7 years following the last surgery and 20 years after the initial visit.
- 13 August 2023
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 49 (11) , 2761-2765
Fertility‐sparing management of stage IIIC serous borderline ovarian tumor: A case report of a 20‐year follow‐up
Multimodal treatment, including assisted reproductive technology, is necessary in young patients with advanced borderline ovarian tumors. However, the details of long-term follow-up cases have not been reported. In this report, a 19-year-old patient presented with a stage IIIC serous borderline tumor. The patient underwent five fertility-sparing surgeries. The tumor did not respond to any of the three lines of chemotherapy administered. Serological and radiological responses were observed following hormonal treatment with leuprorelin, followed by a fourth surgery. Before the planned fifth surgery for complete resection of both adnexa, cryopreservation of the fertilized eggs was performed. At age 36, when the disease-free interval exceeded the previous one, we proposed embryo transfer; however, she declined fertility treatment. The patient had developed rheumatoid arthritis and childbirth not a priority. The patient had lived without any evidence of disease for 7 years following the last surgery and 20 years after the initial visit.
- 26 July 2023
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 43 (8) , 3693-3699
Medroxyprogesterone as the Initial Systemic Treatment of Recurrent Endometrial Cancer: A Single Institutional Study
Background/Aim: Hormonal treatment is the preferred initial systemic therapy for patients with advanced or recurrent G1 or G2 endometrial cancer (EC) in terms of efficacy, toxicity, and economy. Few reports are available on the topic and we, therefore, conducted a retrospective study. Patients and Methods: Patients with EC who received high-dose medroxyprogesterone (MPA) at our Hospital between January 2010 and December 2022 were reviewed. Patients who were treated for fertility preservation or had a history of systemic chemotherapy other than adjuvant therapy were excluded. Results: Sixteen patients who were eligible for study inclusion had recurrent G1 or G2 EC. Their median age was 65 years (range=51-82 years), median body mass index was 22.6 kg/m2 (range=15.3-43.2 kg/m2), and all patients had an ECOG Performance Status of 0. All patients received 200 mg/day of MPA, and eight patients concomitantly received 100 mg/day of aspirin. None of the patients experienced severe adverse events. One patient had grade 2 deep vein thrombosis. Two patients discontinued MPA treatment because of adverse events. The response rate was 44% [95% confidence interval (CI)=20-68%] and median progression-free survival (PFS) was 6.9 months (95% CI=7.5-26 months). Four of 16 patients had PFS longer than 12 months, all of whom had positive tissue estrogen receptor (ER) and progesterone receptor (PR), and PFS at 2 years was 35% (95% CI=10.2-59.8%). Conclusion: Hormone therapy is effective long-term in ER- and PR-positive EC and can be recommended as initial systemic therapy. Toxicity is mild and manageable.
- 26 July 2023
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 43 (8) , 3693-3699
Medroxyprogesterone as the Initial Systemic Treatment of Recurrent Endometrial Cancer: A Single Institutional Study
Background/Aim: Hormonal treatment is the preferred initial systemic therapy for patients with advanced or recurrent G1 or G2 endometrial cancer (EC) in terms of efficacy, toxicity, and economy. Few reports are available on the topic and we, therefore, conducted a retrospective study. Patients and Methods: Patients with EC who received high-dose medroxyprogesterone (MPA) at our Hospital between January 2010 and December 2022 were reviewed. Patients who were treated for fertility preservation or had a history of systemic chemotherapy other than adjuvant therapy were excluded. Results: Sixteen patients who were eligible for study inclusion had recurrent G1 or G2 EC. Their median age was 65 years (range=51-82 years), median body mass index was 22.6 kg/m2 (range=15.3-43.2 kg/m2), and all patients had an ECOG Performance Status of 0. All patients received 200 mg/day of MPA, and eight patients concomitantly received 100 mg/day of aspirin. None of the patients experienced severe adverse events. One patient had grade 2 deep vein thrombosis. Two patients discontinued MPA treatment because of adverse events. The response rate was 44% [95% confidence interval (CI)=20-68%] and median progression-free survival (PFS) was 6.9 months (95% CI=7.5-26 months). Four of 16 patients had PFS longer than 12 months, all of whom had positive tissue estrogen receptor (ER) and progesterone receptor (PR), and PFS at 2 years was 35% (95% CI=10.2-59.8%). Conclusion: Hormone therapy is effective long-term in ER- and PR-positive EC and can be recommended as initial systemic therapy. Toxicity is mild and manageable.
- Open Access
- 1 July 2023
- Published by Medknow in Gynecology and Minimally Invasive Therapy
- Vol. 12 (3) , 175-178
Weight-Loss Interventions and Levonorgestrel Intrauterine System Implantation for Early-Stage Endometrial Cancer and Atypical Endometrial Hyperplasia to Reduce Perioperative Risk of Severely Obese Patients
Endometrial cancer (EC) and atypical endometrial hyperplasia (AEH) are associated with obesity, which increases the perioperative morbidity and surgical difficulties in laparoscopic and robotic surgery. Weight-loss interventions (WLIs) are likely to reduce morbidity; however, delayed surgery may cause cancer progression. To minimize the tumor progression, levonorgestrel intrauterine system (LNG-IUS) with minimal side effects was used until the planned surgery. During 2016 and 2021, we conducted preoperative management of WLI using LNG-IUS for seven highly obese women with a body mass index (BMI) ≥35 kg/m2 who had AEH and EC with Grade 1 and no myometrial invasion on magnetic resonance imaging. In three of the seven patients, the BMI decreased by more than 5. Two patients with AEH achieved remission after LNG-IUS placement and requested conservative management. Five patients with EC underwent laparoscopic hysterectomy, without perioperative complications.
- 1 July 2023
- Published by Medknow in Gynecology and Minimally Invasive Therapy
- Vol. 12 (3) , 175-178
Open AccessWeight-Loss Interventions and Levonorgestrel Intrauterine System Implantation for Early-Stage Endometrial Cancer and Atypical Endometrial Hyperplasia to Reduce Perioperative Risk of Severely Obese Patients
Endometrial cancer (EC) and atypical endometrial hyperplasia (AEH) are associated with obesity, which increases the perioperative morbidity and surgical difficulties in laparoscopic and robotic surgery. Weight-loss interventions (WLIs) are likely to reduce morbidity; however, delayed surgery may cause cancer progression. To minimize the tumor progression, levonorgestrel intrauterine system (LNG-IUS) with minimal side effects was used until the planned surgery. During 2016 and 2021, we conducted preoperative management of WLI using LNG-IUS for seven highly obese women with a body mass index (BMI) ≥35 kg/m2 who had AEH and EC with Grade 1 and no myometrial invasion on magnetic resonance imaging. In three of the seven patients, the BMI decreased by more than 5. Two patients with AEH achieved remission after LNG-IUS placement and requested conservative management. Five patients with EC underwent laparoscopic hysterectomy, without perioperative complications.
- 25 April 2023
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 43 (5) , 2091-2101
Comprehensive Genomic Profiling Detects Hereditary Cancers and Confers Survival Advantage in Patients With Gynaecological Cancers
Background/Aim: The clinical benefits of comprehensive genomic profiling (CGP) of tumours in patients with gynaecological cancers remain unknown. We investigated the utility of CGP in assessing patient survival and its efficacy in detecting hereditary cancers in gynaecological patients. Patients and Methods: We retrospectively analysed the medical records of 104 gynaecological patients who underwent CGP between August 2018 and December 2022. The detection of actionable and accessible genomic alterations and administration of targeted therapy, as recommended by the molecular tumour board (MTB), were assessed. The overall survival (after second-line treatment in cervical and endometrial carcinomas and after platinum-resistant recurrence in ovarian carcinoma) was compared between patients with or without administration of MTB-recommended genotype-matched therapy. Germline findings were assessed using a variant allele frequency–tumour content graph. Results: Among 104 patients, actionable and accessible genomic alterations were observed in 53 patients. Matched therapy was applied in 21 patients, comprising administration of repurposing itraconazole (n=7), immune checkpoint inhibitors (n=7), poly (ADP-ribose) polymerase inhibitors (n=5), and others (n=2). The median overall survival of patients receiving and not receiving matched therapy were 19.3 months and 11.2 months, respectively (p=0.036, hazard ratio=0.48). Among 12 patients with hereditary cancers, 11 patients were previously undiagnosed. Seven patients had hereditary breast and ovarian cancer, and five had other cancer. Conclusion: The implementation of CGP testing prolonged overall survival in gynaecological cancer as well as provided an opportunity for genetic counselling for newly-diagnosed patients with hereditary cancers and their families.
- 25 April 2023
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 43 (5) , 2091-2101
Comprehensive Genomic Profiling Detects Hereditary Cancers and Confers Survival Advantage in Patients With Gynaecological Cancers
Background/Aim: The clinical benefits of comprehensive genomic profiling (CGP) of tumours in patients with gynaecological cancers remain unknown. We investigated the utility of CGP in assessing patient survival and its efficacy in detecting hereditary cancers in gynaecological patients. Patients and Methods: We retrospectively analysed the medical records of 104 gynaecological patients who underwent CGP between August 2018 and December 2022. The detection of actionable and accessible genomic alterations and administration of targeted therapy, as recommended by the molecular tumour board (MTB), were assessed. The overall survival (after second-line treatment in cervical and endometrial carcinomas and after platinum-resistant recurrence in ovarian carcinoma) was compared between patients with or without administration of MTB-recommended genotype-matched therapy. Germline findings were assessed using a variant allele frequency–tumour content graph. Results: Among 104 patients, actionable and accessible genomic alterations were observed in 53 patients. Matched therapy was applied in 21 patients, comprising administration of repurposing itraconazole (n=7), immune checkpoint inhibitors (n=7), poly (ADP-ribose) polymerase inhibitors (n=5), and others (n=2). The median overall survival of patients receiving and not receiving matched therapy were 19.3 months and 11.2 months, respectively (p=0.036, hazard ratio=0.48). Among 12 patients with hereditary cancers, 11 patients were previously undiagnosed. Seven patients had hereditary breast and ovarian cancer, and five had other cancer. Conclusion: The implementation of CGP testing prolonged overall survival in gynaecological cancer as well as provided an opportunity for genetic counselling for newly-diagnosed patients with hereditary cancers and their families.
- 25 April 2023
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 43 (5) , 1981-1984
Itraconazole Modulates Phospholipid Levels in Tumor-associated Macrophages
Background/Aim: Itraconazole, an antifungal drug, repolarizes pro-tumorigenic M2 tumor-associated macrophages to anti-tumorigenic M1-like phenotypes, thereby inhibiting the proliferation of cancer cells; however, the underlying mechanism remains unclear. Therefore, we investigated the effect of itraconazole on membrane-associated lipids in tumor-associated macrophages (TAM). Materials and Methods: M1 and M2 macrophages were derived from the human monocyte leukemia cell line (THP-1) and cultured with or without 10 μM itraconazole. Cells were homogenized and subjected to liquid chromatography/mass spectrometry (LC/MS) analysis to estimate the glycerophospholipid levels in the cells. Results: Lipidomic analysis results, displayed on a volcano plot, revealed that itraconazole-induced altered phospholipid composition, with more pronounced changes in M2 macrophages than in M1. Notably, itraconazole significantly increased intracellular phosphatidylinositol and lysophosphatidylcholine levels in M2 macrophages. Conclusion: Itraconazole modulates the lipid metabolism of TAMs, which could have implications for the development of novel cancer therapies.
- 25 April 2023
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 43 (5) , 1981-1984
Itraconazole Modulates Phospholipid Levels in Tumor-associated Macrophages
Background/Aim: Itraconazole, an antifungal drug, repolarizes pro-tumorigenic M2 tumor-associated macrophages to anti-tumorigenic M1-like phenotypes, thereby inhibiting the proliferation of cancer cells; however, the underlying mechanism remains unclear. Therefore, we investigated the effect of itraconazole on membrane-associated lipids in tumor-associated macrophages (TAM). Materials and Methods: M1 and M2 macrophages were derived from the human monocyte leukemia cell line (THP-1) and cultured with or without 10 μM itraconazole. Cells were homogenized and subjected to liquid chromatography/mass spectrometry (LC/MS) analysis to estimate the glycerophospholipid levels in the cells. Results: Lipidomic analysis results, displayed on a volcano plot, revealed that itraconazole-induced altered phospholipid composition, with more pronounced changes in M2 macrophages than in M1. Notably, itraconazole significantly increased intracellular phosphatidylinositol and lysophosphatidylcholine levels in M2 macrophages. Conclusion: Itraconazole modulates the lipid metabolism of TAMs, which could have implications for the development of novel cancer therapies.
- Open Access
- 22 February 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (8) , e32880
Combination therapy of oral cyclophosphamide and bevacizumab for patients with recurrent ovarian and peritoneal cancer
Chemotherapy for patients with recurrent cancer aims to obtain survival benefits, relieve symptoms, and improve quality of life. We used oral cyclophosphamide and bevacizumab (BEV) combination therapy in recurrent ovarian and peritoneal cancer cases, where standard chemotherapy was infeasible. Subsequently, we evaluated the safety and efficacy of this treatment. Between August 2014 and June 2020, patients received the following regimen: oral cyclophosphamide 50 mg daily and intravenous cyclic BEV 15 mg/kg every 3 weeks. Data from 2 facilities were retrospectively analyzed. Twenty-two patients were enrolled (20 with ovarian cancer and two with peritoneal cancer). The median follow-up period and age were 18.9 months (range, 5.0–51.5) and 60 years (range 37–81), respectively. Sixteen patients had platinum resistance. The median number of previous chemotherapy regimens was 2.5 (range 0–5). The median implementation cycle was five (range 2–14). Eighteen patients discontinued treatment due to side effects (3 patient) and disease progression (15 patient). Grade 2 toxicities included neutropenia (1 patient), proteinuria (1 patient), hypertension (2 patient), and esophagitis (1 patient). Two patients had complete response and one had a partial response. Five patients had stable disease. The response rate in platinum-sensitive recurrence was 33.3%, and 7.1% in platinum-resistant recurrence, and a clinical benefit was found in 8 (36.3%) patients. The median PFS and overall survival from cyclophosphamide and BEV initiation was 5.3 months (range, 0.8–23.5) and 9.2 months (range, 4.8–51.5), respectively. The combination of oral cyclophosphamide and BEV does not have a high response rate, but is well-tolerated and can be used safely in patients who are difficult to treat after second-line chemotherapy. Data from 2 facilities were retrospectively analyzed.
- 22 February 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (8) , e32880
Open AccessCombination therapy of oral cyclophosphamide and bevacizumab for patients with recurrent ovarian and peritoneal cancer
Chemotherapy for patients with recurrent cancer aims to obtain survival benefits, relieve symptoms, and improve quality of life. We used oral cyclophosphamide and bevacizumab (BEV) combination therapy in recurrent ovarian and peritoneal cancer cases, where standard chemotherapy was infeasible. Subsequently, we evaluated the safety and efficacy of this treatment. Between August 2014 and June 2020, patients received the following regimen: oral cyclophosphamide 50 mg daily and intravenous cyclic BEV 15 mg/kg every 3 weeks. Data from 2 facilities were retrospectively analyzed. Twenty-two patients were enrolled (20 with ovarian cancer and two with peritoneal cancer). The median follow-up period and age were 18.9 months (range, 5.0–51.5) and 60 years (range 37–81), respectively. Sixteen patients had platinum resistance. The median number of previous chemotherapy regimens was 2.5 (range 0–5). The median implementation cycle was five (range 2–14). Eighteen patients discontinued treatment due to side effects (3 patient) and disease progression (15 patient). Grade 2 toxicities included neutropenia (1 patient), proteinuria (1 patient), hypertension (2 patient), and esophagitis (1 patient). Two patients had complete response and one had a partial response. Five patients had stable disease. The response rate in platinum-sensitive recurrence was 33.3%, and 7.1% in platinum-resistant recurrence, and a clinical benefit was found in 8 (36.3%) patients. The median PFS and overall survival from cyclophosphamide and BEV initiation was 5.3 months (range, 0.8–23.5) and 9.2 months (range, 4.8–51.5), respectively. The combination of oral cyclophosphamide and BEV does not have a high response rate, but is well-tolerated and can be used safely in patients who are difficult to treat after second-line chemotherapy. Data from 2 facilities were retrospectively analyzed.
- 25 January 2023
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 43 (2) , 569-580
Itraconazole Repolarizes Tumor-associated Macrophages and Suppresses Cervical Cancer Cell Growth
Background/Aim: Itraconazole (ITZ), an antifungal agent, has been reported to have anti-tumor effects in patients with multiple cancer types. We investigated the involvement of tumor-associated macrophages (TAMs) in its tumor-agnostic mechanism. Materials and Methods: M1 and M2 macrophages were established from human monocyte leukemia cell line (THP-1) and their phenotypes were determined morphologically. Cell membrane antigens and secreted proteins were evaluated by western blots and enzyme-linked immunosorbent assay, respectively. The proteomic profiling of cells was done by liquid chromatography with tandem mass spectrometry and analyzed. Viability of cervical cancer cells (CaSki) was evaluated after addition of the supernatant of M2 macrophages and during co-culture with M2 macrophages, with or without 10−5 M ITZ. Results: Co-culture of M1 macrophages inhibited the proliferation of CaSki cells (p=0.012), while that of M2 macrophages promoted their proliferation (p<0.0001). After treatment of M2 macrophages with ITZ for 24 h, they changed into M1-like shape with decreased expression of cluster of differentiation 163 (CD163) and chemokine ligand 18 (CCL18). The M1-like shape was maintained for 7 weeks of ITZ treatment and reverted to original after ITZ removal. Proteomic analysis of ITZ treated-M2 macrophages also demonstrated M1-like signature including the elevated levels of tumor necrosis factor (TNF)-related proteins. After treatment with ITZ, both the supernatant of the M2 macrophages and the co-culture with M2 macrophages significantly inhibited the proliferation of CaSki cells (each, p<0.0001). Conclusion: ITZ repolarized M2 macrophages to M1 type and suppressed cervical cancer cell growth demonstrating TAM-mediated anti-cancer activity of ITZ.
- 25 January 2023
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 43 (2) , 569-580
Itraconazole Repolarizes Tumor-associated Macrophages and Suppresses Cervical Cancer Cell Growth
Background/Aim: Itraconazole (ITZ), an antifungal agent, has been reported to have anti-tumor effects in patients with multiple cancer types. We investigated the involvement of tumor-associated macrophages (TAMs) in its tumor-agnostic mechanism. Materials and Methods: M1 and M2 macrophages were established from human monocyte leukemia cell line (THP-1) and their phenotypes were determined morphologically. Cell membrane antigens and secreted proteins were evaluated by western blots and enzyme-linked immunosorbent assay, respectively. The proteomic profiling of cells was done by liquid chromatography with tandem mass spectrometry and analyzed. Viability of cervical cancer cells (CaSki) was evaluated after addition of the supernatant of M2 macrophages and during co-culture with M2 macrophages, with or without 10−5 M ITZ. Results: Co-culture of M1 macrophages inhibited the proliferation of CaSki cells (p=0.012), while that of M2 macrophages promoted their proliferation (p<0.0001). After treatment of M2 macrophages with ITZ for 24 h, they changed into M1-like shape with decreased expression of cluster of differentiation 163 (CD163) and chemokine ligand 18 (CCL18). The M1-like shape was maintained for 7 weeks of ITZ treatment and reverted to original after ITZ removal. Proteomic analysis of ITZ treated-M2 macrophages also demonstrated M1-like signature including the elevated levels of tumor necrosis factor (TNF)-related proteins. After treatment with ITZ, both the supernatant of the M2 macrophages and the co-culture with M2 macrophages significantly inhibited the proliferation of CaSki cells (each, p<0.0001). Conclusion: ITZ repolarized M2 macrophages to M1 type and suppressed cervical cancer cell growth demonstrating TAM-mediated anti-cancer activity of ITZ.